MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jscai.2025.103790

Медицинская библиотека · Journal of the Society for Cardiovascular Angiography & Interventions · 2025

Impact of Pre-PCI Activated Clotting Time on Outcomes of Bivalirudin Versus Heparin During Primary PCI.

Liu Meili, Li Yi, Liang Zhenyang, Qiu Miaohan, Li Jing, Sun Haiyan, Li Yuzi, Jin Yuanzhe, Ma Xiaolei, Li Feng, Xiang Qiancai, Yang Haibo, Wang Lixin, Bai Ming, Fan Jili, Cai Haipeng, Bai Xue, Han Yaling, Stone Gregg W

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The BRIGHT-4 trial demonstrated that procedural anticoagulation with bivalirudin followed by a median 3-hour high-dose infusion reduced the 30-day composite of all-cause mortality or Bleeding Academic Research Consortium (BARC) types 3 to 5 bleeding compared with heparin alone among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI). Whether the pre-PCI activated clotting time (ACT) influences this benefit is unknown. In the study, we aim to investigate whether the pre-PCI ACT levels affected the outcomes with each anticoagulant.

METHODS

The BRIGHT-4 protocol required a pre-PCI ACT to be assessed 5 minutes after study medications were administered with additional anticoagulant boluses given to achieve an ACT ≥225 seconds. In the present prespecified analysis, 30-day outcomes were analyzed according to the initial pre-PCI ACT level.

RESULTS

The initial pre-PCI ACT was <225 seconds in 971 of 5461 (17.8%) patients, including 123 of 2776 (4.4%) after bivalirudin and 848 of 2685 (31.6%) after heparin (P < .0001). Among 4490 of 5461 (82.2%) patients with an initial ACT ≥225 seconds, bivalirudin was associated with a lower incidence of BARC types 3 to 5 bleeding (0.2% vs 0.8%; adjusted hazard ratio, 0.22; 95% CI, 0.08-0.62; P = .004) and stent thrombosis (0.4% vs 1.0%; adjusted hazard ratio, 0.38; 95% CI, 0.18-0.81; P = .01) compared with heparin. Outcomes were not significantly different in bivalirudin and heparin-treated patients with an initial pre-PCI ACT <225 seconds. There were no significant interactions present between pre-PCI ACT strata and the treatment group for the primary end point or any of the secondary end points.

CONCLUSIONS

Among patients with ST-segment elevation myocardial infarction undergoing PCI with radial artery access, procedural anticoagulation with bivalirudin was associated with lower 30-day rates of mortality, BARC types 3 to 5 bleeding, and stent thrombosis compared with heparin, findings that were consistent regardless of the pre-PCI ACT level.

Для цитирования: Liu Meili, Li Yi, Liang Zhenyang, Qiu Miaohan, Li Jing, Sun Haiyan, Li Yuzi, Jin Yuanzhe, Ma Xiaolei, Li Feng, Xiang Qiancai, Yang Haibo, Wang Lixin, Bai Ming, Fan Jili, Cai Haipeng, Bai Xue, Han Yaling, Stone Gregg W. Impact of Pre-PCI Activated Clotting Time on Outcomes of Bivalirudin Versus Heparin During Primary PCI.. Journal of the Society for Cardiovascular Angiography & Interventions. 2025. DOI: 10.1016/j.jscai.2025.103790.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.